Fig. 4

GLIPR1 knockdown enhanced CAR-T treatment in vitro and in vivo. A and B In-vitro cytotoxicity of 15B6 and 15B6ss CAR-T against gastric cancer cell lines HGC27 and MKN45 with GLIPR1 transient knockdown under effector-to-target ratio of 2:1 for 24 h by bioluminescence assay. C In-vitro cytotoxicity of 15B6 and 15B6ss CAR-T on HGC27 with GLIPR1 stable overexpression (OE-GLIPR1) under effector-to-target ratio of 2:1 for 24 h by bioluminescence assay. D In-vitro cytotoxicity of 15B6 and 15B6ss CAR-T on HGC27 with GLIPR1 stable knockdown (SH-GLIPR1) under effector-to-target ratio of 2:1 for 24 h by bioluminescence assay. E and F Cytokine production of CAR-T cells co-cultured with HGC27-Gsh under the effector-to-target ratio of 2:1 for 24 h by ELISA assay. (G) Experiment setup for (H) and (I). Tumor volume (H) and Mice body weight (I) of HGC27-sc and HGC27-Gsh mouse xenografts after treatment with 2 × 10⁶ 15B6 or 15B6ss CAR-T cells. Sc means scramble. Gsh means shRNA for GLIPR1. J Experiment setup for (K) and (L). Tumor volume (K) and Mice body weight (L) of HGC27-sc and HGC27-Gsh mouse xenografts after treatment with 5 × 10.⁶ 15B6 or 15B6ss CAR-T cells. Asterisks in figures represented significant difference (*p < 0.05, **p < 0.01) between two groups, calculated using one-way ANOVA test by IBM SPSS statistics 20